Sorry to be a pain in the rear, but there was no "denial" by psychiatry. The company inactivated the application. This may be a knit, however it may be usefull at some point in the future.
Neuro - What is your sense as to where Stoll is heading this year. Assuming good RD results, would you anticipate Stoll looking for a buyout or would you anticipate Stoll wanting to keep COR going as an independent.
I recognize that many nuances may drive the direction, so that an answer is very much context driven. If you can give it a shot, your response would be most appreciated.
News 
Market Data 
Discover 
AI
